A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer

BACKGROUND. Preclinical studies demonstrated that non-nucleoside reverse transcriptase inhibitors used for the treatment of HIV could antagonize tumor development. This led us to assess the efficacy of efavirenz in patients with metastatic castration-resistant prostate cancer (mCRPC) in a multicente...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Houédé, Nadine, Pulido, Marina, Mourey, Loic, Joly, Florence, Ferrero, Jean-Marc, Bellera, Carine, Priou, Frank, Lalet, Caroline, Laroche-Clary, Audrey, Raffin, Mireille Canal, Ichas, François, Puech, Alain, Piazza, Pierre Vincenzo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2014
Gaiak:
Clinical Trial Results
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4257751/
https://ncbi.nlm.nih.gov/pubmed/25355844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0345
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak